Who are Eurartesim dispersible oral tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coartem, Coartem, Qualaquin, Malarone, Mepron, Halfan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eurartesim-dispersible-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Eurartesim dispersible oral tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eurartesim dispersible oral tablet (Eurartesim dispersible oral tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antimalarial. Area: Infectious Disease.

phase 2 antimalarial hemozoin formation in Plasmodium parasites Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Eurartesim dispersible oral tablet (Eurartesim dispersible oral tablet) — sigma-tau i.f.r. S.p.A.. Eurartesim is a fixed-dose combination of dihydroartemisinin and piperaquine, targeting the hemozoin formation in Plasmodium parasites to treat malaria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eurartesim dispersible oral tablet TARGET	Eurartesim dispersible oral tablet	sigma-tau i.f.r. S.p.A.	phase 2	antimalarial	hemozoin formation in Plasmodium parasites
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01
Mepron	ATOVAQUONE		marketed	Antimalarial [EPC]	ATP-binding cassette sub-family G member 2	1992-01-01
Halfan	HALOFANTRINE	GSK	marketed	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antimalarial class)

sigma-tau i.f.r. S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eurartesim dispersible oral tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/eurartesim-dispersible-oral-tablet. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab